Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 301–400 of 1,000
Paladhi, A., Daripa, S., Mondal, I., & Hira, S. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988071 · Cited by 28
The development of new agents and molecular classifications
Cutsem, E. V., & Ducreux, M. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.217 · Cited by 29
Trifluridine/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer.
Kish, T. D., & Uppal, P. (2016) · PubMed · Cited by 28
TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
Petrelli, F., Barni, S., Bertocchi, P., & Zaniboni, A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2409-8 · Cited by 27
Self-citationPierantoni, C., Cosentino, L., & Ricciardiello, L. (2024) · Digestive Diseases · doi:10.1159/000538511 · Cited by 32
Updates on the Management of Colorectal Cancer in Older Adults
O'Donnell, C., Hubbard, J. M., & Jin, Z. (2024) · Cancers · doi:10.3390/cancers16101820 · Cited by 33
Oral drugs in the treatment of metastatic colorectal cancer
Kwakman, J. J. M., & Punt, C. J. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1186649 · Cited by 27
Rossini, D., Germani, M. M., Pagani, F., Pellino, A., Dell’Aquila, E., Bensi, M., Liscia, N., Moretto, R., Boccaccino, A., Prisciandaro, M., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.03.009 · Cited by 30
Self-citationMatsuoka, H., Yamada, T., Ohta, R., Yoshida, Y., Watanabe, T., Takahashi, M., Kosugi, C., Fukazawa, A., Kuramochi, H., Matsuda, A., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02243-4 · Cited by 26
Conca, V., Ciracì, P., Boccaccio, C., Minelli, A., Antoniotti, C., & Cremolini, C. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102735 · Cited by 28
Chemotherapy for advanced gastric cancer: future perspective in Japan
Shitara, K. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0648-7 · Cited by 26
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102)
Lee, J. J., & Chu, E. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.003 · Cited by 26
Ryeznik, Y. V., & Sverdlov, O. (2018) · Statistics in Medicine · doi:10.1002/sim.7817 · Cited by 32
Zhu, J., Zhou, R., & binglan, Z. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02964-6 · Cited by 31
Zulfiker, A. H. M., Belcher, A., Li, O. Q., Yue, H., Gupta, A. S., & Li, W. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315109 · Cited by 27
TAS-102: A Novel Antimetabolite for the 21st Century
Uboha, N. V., & Höchster, H. S. (2015) · Future Oncology · doi:10.2217/fon.15.276 · Cited by 27
Update on the management of elderly patients with colorectal cancer
Soler, G., Valera, J. S., Viana-Alonso, A., Urtasún, J. A., García-Escobar, I., Gómez‐España, M. A., Guillén‐Ponce, C., Molina-Garrido, M. J., & Sarrió, R. G. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03243-0 · Cited by 37
Kitao, H., Morodomi, Y., Niimi, S., Kiniwa, M., Shigeno, K., Matsuoka, K., Kataoka, Y., Iimori, M., Tokunaga, E., Saeki, H., et al. (2016) · Scientific Reports · doi:10.1038/srep25286 · Cited by 25
Chemotherapy re-challenge response rate in metastatic colorectal cancer
Chambers, A. E., Frick, J. C., Tanner, N., Gerkin, R. D., Kundranda, M. N., & Dragovich, T. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.04.08 · Cited by 26
Chen, J., Wang, J., Lin, H. L., & Peng, Y. (2019) · Medical Science Monitor · doi:10.12659/msm.918411 · Cited by 26
Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
Lam, M., Lum, C., Latham, S., Smith, S. T., Prenen, H., & Segelov, E. (2020) · Cancer Management and Research · doi:10.2147/cmar.s213236 · Cited by 29
Self-citationChemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer
Martín-Romano, P., Ammari, S., El-Dakdoukti, Y., Baldini, C., Varga, A., Vuagnat, P., Angevin, E., Bahleda, R., Gazzah, A., Champiat, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.030 · Cited by 26
Locoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection
Uhlig, J., Lukovic, J., Dawson, L. A., Patel, R. A., Cavnar, M. J., & Kim, H. S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320519 · Cited by 27
Ducreux, M. P., Bennouna, J., Adenis, A., Conroy, T., Lièvre, A., Portales, F., Jeanes, J., Li, L., & Romano, A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3193-5 · Cited by 27
Patel, A. K., Duh, M. S., Barghout, V. E., Yenikomshian, M. A., Xiao, Y., Wynant, W., Tabesh, M., & Fuchs, C. S. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.04.002 · Cited by 25
Chen, E. Y., Blanke, C. D., Haller, D. G., Benson, A. B., Dragovich, T., Lenz, H.-J., Robles, C., Li, H., Mori, M., Mattek, N., et al. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000465 · Cited by 23
Self-citationWhite, J., Carolan‐Rees, G., Dale, M., Morgan, H. E., Patrick, H. E., See, T., Beeton, E. L., Swinson, D., Bell, J. K., Manas, D., et al. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.09.002 · Cited by 27
Mayer, R. J., Höchster, H. S., Cohen, S. J., Winkler, R. E., Makris, L., & Grothey, A. A. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3686-5 · Cited by 25
Self-citationMaximising clinical benefit with adequate patient management beyond the second line in mCRC
Argilés, G., Arnold, D., Prager, G. W., Sobrero, A. F., & Cutsem, E. V. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000495 · Cited by 25
Self-citationNose, Y., Kagawa, Y., Hata, T., Mori, R., Kawai, K., Naito, A., Sakamoto, T., Murakami, K., Katsura, Y., Ohmura, Y., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04129-6 · Cited by 26
Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis
Kwan, J., & Pua, U. (2021) · Cancers · doi:10.3390/cancers13061371 · Cited by 26
Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer
Shitara, K., & Ohtsu, A. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0138 · Cited by 25
Self-citationLi, Y., Chen, X., Li, W., Ye, Y., Du, X., Sun, S., Liu, L., & Zhang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684309 · Cited by 24
“TAS-102 significantly prolonged the OS compared with the placebo group in advanced CRC patients (6, 10).”
BackgroundCSCO guidelines for colorectal cancer version 2024: Updates and discussions
Chen, L., Hu, H., Yuan, Y., & Weng, S. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.03.01 · Cited by 25
Yamaguchi, T., Tsuchihashi, K., Ueno, S., Uehara, K., Taguchi, R., Ito, M., Isobe, T., Imajima, T., Kitazono, T., Tanoue, K., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104108 · Cited by 29
Self-citationCiracì, P., Germani, M. M., Pietrantonio, F., Manca, P., Lonardi, S., Busico, A., Bergamo, F., Burgio, V., Mannavola, F., Donato, S. D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.002 · Cited by 31
Hiyoshi, Y., Miyamoto, Y., Kiyozumi, Y., Eto, K., Nagai, Y., Iwatsuki, M., Iwagami, S., Baba, Y., Yoshida, N., & Baba, H. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01523-w · Cited by 25
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
Strickler, J. H., Rushing, C. N., Uronis, H. E., Morse, M. A., Niedzwiecki, D., Blobe, G. C., Moyer, A. N., Bolch, E. K., Webb, R., Haley, S. T., et al. (2021) · The Oncologist · doi:10.1002/onco.13678 · Cited by 25
Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019
Weng, S., Yuan, Y., Wang, X., Chen, G., Wang, Y., Sheng, W., Li, X., Zhou, A., Zhang, Z., Li, G., et al. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.03.11 · Cited by 28
Faugeras, L., Dili, A., Druez, A., Krug, B., Decoster, C., & D'Hondt, L. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.029 · Cited by 28
Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Giampieri, R., Restivo, A., Pusceddu, V., Prete, M. D., Maccaroni, E., Bittoni, A., Faloppi, L., Andrikou, K., Bianconi, M., Cabras, F., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.011 · Cited by 25
Baba, Y., Tamura, T., Satoh, Y., Gotou, M., Sawada, H., Ebara, S., Shibuya, K., Soeda, J., & Nakamura, K. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12074 · Cited by 23
“Compared with the placebo, TAS-102 provided an overall survival benefit of approximately 2 months in a randomized phase III trial that included patients with refractory (or intolerant) mCRC (Mayer et al., 2015).”
BackgroundUnraveling the complexities of colorectal cancer and its promising therapies – An updated review
Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 30
Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers
Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 28
Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review
Degeling, K., Vu, M., Koffijberg, H., Wong, H., Koopman, M., Gibbs, P., & IJzerman, M. J. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00908-4 · Cited by 23
Takahashi, T., Yamazaki, K., Oki, E., Shiozawa, M., Mitsugi, K., Makiyama, A., Nakamura, M., Ojima, H., Kagawa, Y., Matsuhashi, N., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100093 · Cited by 23
Self-citationTsuji, A., Nakamura, M., Watanabe, T., Manaka, D., Matsuoka, H., Kataoka, M., Takeuchi, M., Ichikawa, W., & Fujii, M. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00845-y · Cited by 25
Systemic therapy for gastric cancer: Perioperative strategies and beyond
Cann, C., & Ciombor, K. K. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26834 · Cited by 23
Cohen, R., Raeisi, M., Chibaudel, B., Shi, Q., Yoshino, T., Zalcberg, J. R., Adams, R., Cremolini, C., Cutsem, E. V., Heinemann, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114160 · Cited by 35
Self-citationNovel therapeutic agents in the treatment of metastatic colorectal cancer
Pai, S. G., & Fuloria, J. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.99 · Cited by 25
Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry
Lee, J. J., Seraj, J., Yoshida, K., Mizuguchi, H., Strychor, S., Fiejdasz, J., Faulkner, T., Parise, R. A., Fawcett, P., Pollice, L., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2965-2 · Cited by 23
Self-citationCosta, T. G., Nuñez, J. E., Felismino, T. C., Boente, L. D. A., & de Mello, C. A. L. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.03.002 · Cited by 25
Direct Analysis of Incorporation of an Anticancer Drug into DNA at Single-Molecule Resolution
Ohshiro, T., Komoto, Y., Konno, M., Koseki, J., Asai, A., Ishii, H., & Taniguchi, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-40504-x · Cited by 23
Ilson, D. H., Tabernero, J. M., Prokharau, A., Arkenau, H., Ghidini, M., Fujitani, K., Cutsem, E. V., Thuss-Patience, P. C., Beretta, G. D., Mansoor, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3531 · Cited by 23
Self-citationAndré, T., Saunders, M. P., Kanehisa, A., Gandossi, E., Fougeray, R., Amellal, N., & Falcone, A. (2020) · Future Oncology · doi:10.2217/fon-2019-0786 · Cited by 23
Self-citationRuan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02274-z · Cited by 22
Ciardiello, D., Mauri, G., Bianchi, A. S., Siena, S., Zampino, M. G., Fazio, N., & Cervantes, A. M. R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102683 · Cited by 25
Huemer, F., Schlintl, V., Hecht, S., Hackl, H., Melchardt, T., Rinnerthaler, G., Greil, R., & Weiß, L. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.04.003 · Cited by 26
Vitale, P., Zanaletti, N., Famiglietti, V., Falco, V. D., Cervantes, A. M. R., Roselló, S., Fenocchio, E., Milanesio, M. C., Lombardi, P., Ciardiello, D., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.06.002 · Cited by 23
Cremolini, C., Montagut, C. O., Ronga, P., Venturini, F., Yamaguchi, K., Stintzing, S., & Sobrero, A. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.946850 · Cited by 25
Self-citationButel-Simoes, L. E., Haw, T. J., Williams, T. D., Sritharan, S., Gadre, P., Herrmann, S. M., Herrmann, J., Ngo, D. T. M., & Sverdlov, A. L. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.17947 · Cited by 24
Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies
Kitsel, Y., Cooke, T., Sotirchos, V. S., & Sofocleous, C. T. (2023) · Cancers · doi:10.3390/cancers15061679 · Cited by 25
Marks, E. I., Tan, C. R. C., Zhang, J., Zhou, L., Yang, Z., Scicchitano, A., & El‐Deiry, W. S. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1113355 · Cited by 22
Takahashi, N., Iwasa, S., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.74 · Cited by 26
Self-citationVelden, D. L. V. D., Opdam, F. L., & Voest, E. E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2783 · Cited by 22
Tanaka, A., Sadahiro, S., Suzuki, T., Okada, K., Saito, G., & Miyakita, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9421 · Cited by 22
Sonbol, M. B., Benkhadra, R., Wang, Z., Firwana, B., Walden, D. M., Mody, K., Hubbard, J. M., Murad, M. H., Ahn, D. H., & Bekaii‐Saab, T. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0189 · Cited by 23
Zhang, Q., Wang, Q., Wang, X., Li, J., Shen, L., & Peng, Z. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03477-x · Cited by 30
Liu, R., Ji, Z., Wang, X., Zhu, L., Xin, J., Ma, L., Zhang, J., Ge, S., Zhang, L., Yang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56748-3 · Cited by 28
Kiesewetter, B., Raderer, M., Steger, G. G., Bartsch, R., Pirker, R., Zöchbauer‐Müller, S., Prager, G. W., Krainer, M., Preusser, M., Schmidinger, M., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000066 · Cited by 23
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
Tabernero, J. M., Cutsem, E. V., Ohtsu, A., Amellal, N., Cadour, S., Fougeray, R., Haffemayer, B., & Mayer, R. J. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000284 · Cited by 21
Self-citationAntiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib
Papadimitriou, M., & PAPADIMITRIOU, C. A. (2021) · Anticancer Research · doi:10.21873/anticanres.14809 · Cited by 23
Moretto, R., Rossini, D., Capone, I., Boccaccino, A., Perrone, F., Tamborini, E., Masi, G., Antoniotti, C., Marmorino, F., Conca, V., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.07.001 · Cited by 25
Self-citationTailored Systemic Therapy for Colorectal Cancer Liver Metastases
Czauderna, C., Luley, K. B., von Bubnoff, N. C. C., & Marquardt, J. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111780 · Cited by 23
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
Bui, Q. L., Mas, L., Hollebecque, A., Tougeron, D., de la Fouchardière, C., Pudlarz, T., Alouani, E. L., Guimbaud, R., Taïeb, J., André, T., et al. (2022) · Cancers · doi:10.3390/cancers14020406 · Cited by 21
Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer
Regenbogen, T., Chen, L., Trinkaus, K. M., Wang‐Gillam, A., Tan, B. R., Amin, M. A., Pedersen, K. S., Park, H., Suresh, R., Lim, K., et al. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.08.16 · Cited by 21
Yang, Q., Huang, Y., Jiang, Z.-M., Wang, H., Li, W., Zhang, B., & Xie, D.-R. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s154220 · Cited by 21
Patel, A. K., Barghout, V. E., Yenikomshian, M. A., Germain, G., Jacques, P., Laliberté, F., & Duh, M. S. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0240 · Cited by 21
Samalin, E., de la Fouchardière, C., Thézenas, S., Boige, V., Senellart, H., Guimbaud, R., Taïeb, J., François, É., Galais, M., Lièvre, A., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.008 · Cited by 22
Nakashima, M., Takeuchi, M., & Kawakami, K. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.05.003 · Cited by 22
Regorafenib in the treatment of colorectal cancer
Majithia, N., & Grothey, A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118054 · Cited by 26
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 23
Camps, C., Badia, X. C., García‐Campelo, R., García‐Foncillas, J., López‐López, R., Massutí, B., Provencio, M., Salazar, R., Virizuela, J. A., & Guillém, V. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00487 · Cited by 23
Sato, T., Osumi, H., Shinozaki, E., Ooki, A., Shimozaki, K., Kamiimabeppu, D., Nakayama, I., Wakatsuki, T., Ogura, M., Takahari, D., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15186 · Cited by 20
Contemporary Surgical Management of Colorectal Liver Metastases
Chandra, P., & Sacks, G. D. (2024) · Cancers · doi:10.3390/cancers16050941 · Cited by 24
Kotani, D., Shitara, K., Kawazoe, A., Fukuoka, S., Kuboki, Y., Bando, H., Okamoto, W., Kojima, T., Doi, T., Ohtsu, A., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.11.005 · Cited by 20
Self-citationCytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level
Kataoka, Y., Iimori, M., Niimi, S., Tsukihara, H., Wakasa, T., Saeki, H., Oki, E., Maehara, Y., & Kitao, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-44399-6 · Cited by 20
Varghese, A. M., Cardin, D. B., Hersch, J., Benson, A. B., Höchster, H. S., Makris, L., Hamada, K., Berlin, J. D., & Saltz, L. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2743 · Cited by 20
Self-citationTsuchihashi, K., Ito, M., Moriwaki, T., Fukuoka, S., Taniguchi, H., Takashima, A., Kumekawa, Y., Kajiwara, T., Yamazaki, K., Esaki, T., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.004 · Cited by 22
Self-citationCapecitabine-Associated Terminal Ileitis
van Hellemond, I. E. G., Thijs, A. M. J., & Creemers, G. (2018) · Case Reports in Oncology · doi:10.1159/000492781 · Cited by 21
Suzuki, N., Tsukihara, H., Nakagawa, F., Kobunai, T., & Takechi, T. (2017) · PubMed · Cited by 20
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer
Qu, F., Wu, S., & Yu, W. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s500281 · Cited by 23
Osumi, H., Ishizuka, N., Takashima, A., Kumekawa, Y., Nakano, D., Shiozawa, M., Denda, T., Sawada, R., Ouchi, K., Wakatsuki, T., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063071 · Cited by 19
Nevala-Plagemann, C., Sama, S., Ying, J., Shen, J., Haaland, B. A., Florou, V., & Garrido‐Laguna, I. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7082 · Cited by 19
Kuboki, Y., Terazawa, T., Masuishi, T., Nakamura, M., Watanabe, J., Ojima, H., Makiyama, A., Kotaka, M., Hara, H., Kagawa, Y., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02212-2 · Cited by 20
Self-citationStucchi, E., Bartolini, M., Airoldi, M., Fazio, R., Daprà, V., Mondello, G., Prete, M. G., Puccini, A., & Santoro, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2336069 · Cited by 20
Ranieri, G., Laface, C., Laforgia, M., Summa, S. D., Porcelli, M., Macina, F., Ammendola, M., Molinari, P., Lauletta, G., Palo, A. D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590707 · Cited by 19
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
Personeni, N., Smiroldo, V., Giunta, E. F., Prete, M. G., Rimassa, L., Bregni, G., & Sclafani, F. (2021) · Cancers · doi:10.3390/cancers13184506 · Cited by 20
Gabizón, A., Tahover, E., Golan, T., Geva, R., Perets, R., Amitay, Y., Shmeeda, H., & Ohana, P. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00897-3 · Cited by 20
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.